Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets), a treatment for fibromyalgia in adults, effective immediately. The agreement adds approximately 21 million Medicare lives, bringing total Medicare coverage to approximately 32 million lives, or 58% of the approximately 55 million Medicare lives in the United States. This expansion is detailed in a recent press release available at https://ibn.fm/Q8TKY.
The broader implications for patients and the healthcare industry are substantial. TONMYA is the first new treatment for fibromyalgia in more than 15 years, and with this agreement, total commercial and government payer coverage now reaches approximately 166 million covered lives, or 53% of the approximately 314 million total U.S. lives. This means more than half of the U.S. population may have access to a novel therapy for a condition that has long lacked innovation. Fibromyalgia affects millions of Americans, often causing widespread pain, fatigue, and cognitive difficulties, and the limited treatment options have left many patients underserved. The expanded coverage could therefore significantly improve quality of life for a large patient population.
To support the increased demand, Tonix has activated approximately 50 new sales representatives, bringing its total sales force to 150 representatives. This commercial expansion follows previous agreements with two leading group purchasing organizations and one major managed Medicare agreement, while TONMYA is also covered by Medicaid in nearly all states. The company's fully integrated, commercial-stage focus on central nervous system (CNS) and immunology treatments positions it to capitalize on this momentum.
For investors, the news signals growing market penetration and potential revenue growth. Tonix's CNS portfolio also includes acute migraine products Zembrace® SymTouch® and Tosymra®, and the company is conducting Phase 2 trials of TONMYA for major depressive disorder and acute stress disorder, as well as advancing TNX-2900 for Prader-Willi syndrome and immunology programs like TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection. These investigational candidates have not been approved for any indication, and their efficacy and safety have not been established.
The announcement was distributed through InvestorWire, a specialized communications platform that provides wire-grade press release syndication. InvestorWire is part of the IBN network, which offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers. For more details on InvestorWire's services, including press release enhancement, visit their website. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
